ArticlePituitary2025
Validation and modification of the PANOMEN 3 classification for predicting long-term recurrence/progression and quality of life in patients with pituitary adenomas: a multicentre retrospective cohort study.
Article in Pituitary, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Can acromegaly be controlled in all cases?Journal of neuroendocrinology · 2026Review
- External validation of the PANOMEN-3 classification for predicting 1-year surgical remission in pituitary adenoma.Pituitary · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePituitary adenomas (PAs) are common intracranial tumours with heterogeneous behaviour. Accurate risk stratification is critical for predicting recurrence/progression and for guiding management. The pituitary adenoma nomenclature 3 (PANOMEN 3) classification, introduced in 2024, integrates clinical, radiological, and pathological factors; however, its prognostic utility and histopathological criteria remain uncertain.
methodsThis multicentre retrospective cohort study included 804 patients with PAs surgically treated between January 2010 and December 2023. Patients were classified using the original PANOMEN 3 system and a modified system incorporating silent corticotroph adenomas (SCAs) as high-risk subtypes, revised proliferative activity criteria (Ki-67 ≥ 3%, mitotic index > 2/10 high-power fields, or p53 positivity), and Trouillas clinicopathological grading. Recurrence-free survival was analysed using Kaplan-Meier and Cox regression models. Predictive performance was assessed using receiver operating characteristic curves. Health-related quality of life (HRQoL) was measured using the EuroQol 5 Dimensions-3 Levels (EQ-5D-3 L) and EuroQol Visual Analogue Scale (EQ-VAS) preoperatively and six months postoperatively.
resultsOver a median follow-up of 5.0 years, 169 patients (21.0%) experienced recurrence/progression. The original PANOMEN 3 classification showed moderate predictive accuracy. The modified classification markedly improved predictive performance to match Trouillas' grading. Higher PANOMEN 3 grade was associated with poorer HRQoL outcomes.
conclusionThe PANOMEN 3 classification provides clinically relevant prognostic value for recurrence/progression and postoperative HRQoL in PAs. The inclusion of SCAs and refined proliferative criteria enhanced predictive accuracy and demonstrated its potential as a comprehensive risk stratification tool. Prospective studies, including non-surgical cohorts, are warranted to confirm its generalisability.
Indexed as
Identifiers
41364129What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.